SAM
CHRS icon

Smartleaf Asset Management’s Coherus Oncology CHRS Stock Holding History

Smartleaf Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-880
Closed -$924 – 2936
2024
Q3 		$924 Buy
+880
New +$1.21K ﹤0.01% 2674

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Smartleaf Asset Management's CHRS Position: Q4 2024 in Review

Smartleaf Asset Management sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 880 shares — an estimated $924 sold.

Smartleaf Asset Management first reported a position in CHRS in Q3 2024 and held it in 1 quarter. The position peaked at $924 in Q3 2024. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

  • Smartleaf Asset Management reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
  • Smartleaf Asset Management sold 880 Coherus Oncology shares in Q4 2024, an estimated $924.
  • Smartleaf Asset Management first reported a position in Coherus Oncology in Q3 2024 and held it in 1 quarter.
  • Smartleaf Asset Management's Coherus Oncology position peaked at $924 in Q3 2024.
  • 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on Smartleaf Asset Management's 13F filing for Q4 2024, filed 5 Feb 2025.